Windtree reports positive Phase 2b study on heart failure therapy
WARRINGTON, Pa. - Windtree Therapeutics, Inc. (NASDAQ:WINT), a biotechnology firm specializing in the development of therapies for critical diseases and currently valued at $1.44 million market ...
Too Old to Operate6d
Corticosteroid Administration and Mortality in Cardiogenic Shock
The following is a summary of “Corticosteroids in Cardiogenic Shock: A Retrospective Analysis of the Medical Information Mart ...